<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827553</url>
  </required_header>
  <id_info>
    <org_study_id>2009-014476-21</org_study_id>
    <nct_id>NCT01827553</nct_id>
  </id_info>
  <brief_title>Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy</brief_title>
  <acronym>CONKO-007</acronym>
  <official_title>Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial examines the effectiveness of chemoradiotherapy compared to&#xD;
      chemotherapy alone after induction chemotherapy with 3 cycles of gemcitabine or 6 cycles of&#xD;
      FOLFIRINOX in patients with locally advanced, non resectable and non-metastatic pancreatic&#xD;
      cancer. Chemotherapeutic agent in chemoradiotherapy is gemcitabine administered in 5 cycles,&#xD;
      the agent and its administration for sole chemotherapy is determined by induction&#xD;
      chemotherapy. Operability of tumor is evaluated at week 11 after randomisation. Patients will&#xD;
      be followed for the duration of therapy and for 5 years after the last study treatment.&#xD;
      Overall survival at the end of follow up is defined as primary endpoint. Secondary endpoints&#xD;
      are tumor-free survival, rate of local recurrence or local progression, rate of distant&#xD;
      metastasis, acute and late toxicity of the chemoradiotherapy, quality of life, rate of&#xD;
      remission, rate of curative resections (R0) after chemotherapy and chemoradiotherapy. It is&#xD;
      planned to include a total number of 830 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor-free survival</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of local recurrence or local progression</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of distant metastasis</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicity of the chemoradiotherapy</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of remission</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of curative resections (R0) after chemotherapy and chemoradiotherapy</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of life</measure>
    <time_frame>Participants will be followed for the duration of therapy and for 5 years after the last study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">830</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction chemotherapy with gemcitabine or FOLFIRINOX</intervention_name>
    <description>According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <other_name>all brands of gemcitabine and FOLFIRINOX components are allowed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy, 28 x 1.8 Gy</intervention_name>
    <description>Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy, gemcitabine</intervention_name>
    <description>5 cycles of 300 mg/m^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m^2/d</description>
    <arm_group_label>Induction CT, chemoradiotherapy</arm_group_label>
    <other_name>all brands of gemcitabine are allowed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy</intervention_name>
    <description>Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m^2/d gemcitabine infusions FOLFIRINOX: 6 cycles</description>
    <arm_group_label>Induction CT, chemotherapy</arm_group_label>
    <other_name>all brands of gemcitabine and FOLFIRINOX components are allowed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  histologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
          -  no evidence of distant metastasis based on computed tomography of the thorax and&#xD;
             abdomen&#xD;
&#xD;
          -  non resectable pancreatic cancer&#xD;
&#xD;
          -  no evidence of peritoneal carcinosis&#xD;
&#xD;
          -  ECOG-performance status ≤ 2&#xD;
&#xD;
          -  signed study-specific consent form prior to therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  fertile patients who refuse effective contraception during study treatment&#xD;
&#xD;
          -  synchron second malignant neoplasm except basal cell carcinoma of the skin and&#xD;
             carcinoma in situ of the cervix after curative therapy&#xD;
&#xD;
          -  the Inclusion of patients with prior or concurrent malignancy (≤ 5 years prior to&#xD;
             enrolment in study) must be discussed&#xD;
&#xD;
          -  chronic inflammatory disease of the intestine&#xD;
&#xD;
          -  known allergic reactions on study medication&#xD;
&#xD;
          -  on-treatment participation on other trials&#xD;
&#xD;
          -  insufficient liver function: Bilirubin &gt; 2,0 mg/dl; SGOT, SGPT, alkaline phosphatase,&#xD;
             gGT more than 3 times upper limit of normal (after Stent implantation in case of&#xD;
             obstructive jaundice); cirrhosis of the liver Child B and C&#xD;
&#xD;
          -  insufficient bone marrow function: WBC &lt; 3,0 x 10^9/l, Platelets &gt; 100 x 10^9/l&#xD;
&#xD;
          -  serum creatinine &gt; 1,5 mg/dl, creatinin clearance &lt; 60ml/min (or comparable test)&#xD;
&#xD;
          -  preexisting uncontrolled cardiac disease, signs of cardiac failure, or rhythm&#xD;
             disturbances requiring therapy, myocardial infarction within the past 6 months,&#xD;
             unstable angina pectoris, congestive heart failure, New York Heart Association (NYHA)&#xD;
             class III or IV heart disease&#xD;
&#xD;
          -  neurological and/or psychiatric diseases: stroke, dementia, epilepsy, psychosis&#xD;
&#xD;
          -  active intractable or uncontrollable infection, HIV-infection&#xD;
&#xD;
          -  prior radiotherapy or chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strahlenklinik, Universitätsklinikum Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aachen Universitätsklinikum</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayreuth, Klinikum</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Klinikum Berlin-Lichtenberg</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berlin Charité</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bochum, Augusta-Kranken-Anstalt, Hämatologie/Onkologie</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bochum, St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandenburg Städtisches Klinikum</name>
      <address>
        <city>Brandenburg</city>
        <zip>14770</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bremen Klinikum Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dresden Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlangen Universitätsklinikum</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Esslingen Klinikum, Hämatologie/Onkologie</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankfurt/Main Universitätsklinikum</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freiburg Universitätsklinikum</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrichshafen Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum Oberland, Klinikum Garmisch-Partenkirchen</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <zip>82467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Göttingen Universitätsmedizin</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halle St. Elisabeth und St. Barbara Krankenhaus</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburg Hämatologisch-Onkologischer Schwerpunkt</name>
      <address>
        <city>Hamburg</city>
        <zip>22457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilbronn SLK-Kliniken</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus GmbH</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homburg Universitätsklinikum</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jena Universitätsklinikum</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Köln Universitätsklinikum</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Köln Kliniken</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leer MVM</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leipzig UCCL</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leverkusen Klinikum</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magdeburg Universitätsklinikum</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magdeburg Klinikum</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mainz Universitätsmedizin</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mannheim Universitätsmedizin</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marburg Universitätsklinikum</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>München Großhadern LMU</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Münster Universitätsklinikum</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oldenburg Pius Hospital</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ostfildern Paracelsus Krankenhaus Ruit</name>
      <address>
        <city>Ostfildern</city>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regensburg Krankenhaus Barmherzige Brüder</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regensburg Universitätsklinikum</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stuttgart Klinikum SCC</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stuttgart Marienhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Traunstein Klinikum</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trier Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tübingen Universitätsklinikum</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm Universitätsklinikum</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Würzburg CCC Mainfranken</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 4, 2013</study_first_submitted>
  <study_first_submitted_qc>April 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>FOLFIRINOX</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

